S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.00 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.97 (+2.09%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.00 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.97 (+2.09%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.00 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.97 (+2.09%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.00 (+0.92%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.66 (+0.75%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.97 (+2.09%)
NVDA   530.10 (+0.13%)
BABA   276.76 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
Log in
NASDAQ:AGEN

Agenus Stock Forecast, Price & News

$3.71
+0.20 (+5.70 %)
(As of 11/27/2020 12:59 PM ET)
Add
Compare
Today's Range
$3.51
Now: $3.71
$3.74
50-Day Range
$3.51
MA: $3.96
$4.49
52-Week Range
$1.82
Now: $3.71
$5.63
Volume96,895 shs
Average Volume1.81 million shs
Market Capitalization$705.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFÃ TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Read More
Agenus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400
Employees328

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150.05 million
Book Value($1.09) per share

Profitability

Net Income$-107,660,000.00
Net Margins-192.56%

Miscellaneous

Market Cap$705.46 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$3.71
+0.20 (+5.70 %)
(As of 11/27/2020 12:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Agenus (NASDAQ:AGEN) Frequently Asked Questions

How has Agenus' stock price been impacted by COVID-19 (Coronavirus)?

Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGEN shares have increased by 36.4% and is now trading at $3.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Agenus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agenus
.

What stocks does MarketBeat like better than Agenus?

Wall Street analysts have given Agenus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Agenus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Agenus
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) issued its quarterly earnings data on Tuesday, November, 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.
View Agenus' earnings history
.

What price target have analysts set for AGEN?

3 brokers have issued 1 year target prices for Agenus' stock. Their forecasts range from $6.00 to $8.00. On average, they anticipate Agenus' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price.
View analysts' price targets for Agenus
.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

Who are Agenus' key executives?

Agenus' management team includes the following people:
  • Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 67, Pay $1.19M)
  • Dr. Jennifer Buell, Pres & COO (Age 46, Pay $687.5k)
  • Mr. Evan D. Kearns, VP, Chief Compliance Officer, Gen. Counsel & Sec. (Age 41, Pay $589.03k)
  • Ms. Christine M. Klaskin, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
  • Dr. Marc van Dijk Ph.D., Chief Technology Officer (Age 58)
  • Regina Grebla Ph.D., VP of Investor Relations & Communications
  • Mr. Ozer Baysal, Chief Commercial Officer & Head of HR (Age 64)
  • John Castle, Head of Translational Medicine & Bioinformatics
  • Mr. Paulo Moreira, Global Head of Clinical Operations
  • Mr. Dhan Chand, Scientific Director & Head of Drug Discovery

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.35%), State Street Corp (3.67%), Wells Fargo & Company MN (0.66%), Charles Schwab Investment Management Inc. (0.55%), Morgan Stanley (0.49%) and Assenagon Asset Management S.A. (0.44%).
View institutional ownership trends for Agenus
.

Which major investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Cadence Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Cardinal Strategic Wealth Guidance, TD Asset Management Inc., Wells Fargo & Company MN, AQR Capital Management LLC, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Agenus
.

Which major investors are buying Agenus stock?

AGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Assenagon Asset Management S.A., Morgan Stanley, Trellus Management Company LLC, Cubist Systematic Strategies LLC, Squarepoint Ops LLC, State Street Corp, and Great West Life Assurance Co. Can.
View insider buying and selling activity for Agenus
.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $3.71.

How big of a company is Agenus?

Agenus has a market capitalization of $705.46 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 328 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.